US9555027 — Pharmaceutical composition
Method of Use · Assigned to Sumitomo Dainippon Pharma Co Ltd · Expires 2026-05-26 · 0y remaining
What this patent protects
This patent protects a pharmaceutical composition for oral administration that includes lurasidone hydrochloride as an active ingredient.
USPTO Abstract
A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1â²R,2â²S,3â²R,4â²S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-543 |
— | lurasidone-hydrochloride |
U-543 |
— | lurasidone-hydrochloride |
U-543 |
— | lurasidone-hydrochloride |
U-543 |
— | lurasidone-hydrochloride |
U-543 |
— | lurasidone-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.